By: Erica Dimitropoulos Co-Copy Editor [Content- Focused]  – On February 14, 2014, elosulfase alfa (Vimizim™) became an FDA-approved enzyme replacement therapy for Morquio A Syndrome, a type of mucopolysaccharidosis (MPS IVA).1 Elosulfase alfa was granted priority review and was also the first drug to receive the Rare Pediatric Disease Priority Review Voucher that motivates the development…

By: Tamara Yunusova, Senior Staff Editor – After a lengthy fifteen-year hiatus in recombinant drug approvals, FDA-approved Recombinant Coagulation Factor IX (Rixubis) has mounted to the forefront of Hemophilia B drug therapy. The recombinant coagulation factor gained orphan drug approval on June 26, 2013 for routine prophylaxis, control of bleeding episodes, and perioperative management in…

By: Steve Soman, Co-Editor-in-Chief – Varicella Zoster Immune Globulin (Varizig®) was approved by the FDA on December 21st of 2012. The Canadian pharmaceutical company Cangene Corporation, which is owned in-part by Apotex Inc., markets the new product.  The drug was approved by the Food and Drug Administration (FDA) to reduce “the severity of chicken pox…